SkinBioTherapeutics

SBTX · AIM · Health Care · mcap £16m · 5.3p

Beta Briefing, track record and bull & bear case are not ready for SkinBioTherapeutics yet.

We follow 817 UK small caps and every one of their announcements – often hundreds per company. 33 companies are already wired into a briefing: browse them.

Mark H Dixon and Diana Dixon 7 Jan – 27 Jul · 9 notices

below 3% → 29.3%

share price at the notices 9.8–20.5p · now 5.3p 7 Jan 2026 20 Jan 2026 29 Jan 2026 12 Feb 2026 13 Mar 2026 1 Apr 2026 12 May 2026 21 Jul 2026 27 Jul 2026

Mark H Dixon 13 Oct – 29 Dec · 6 notices

below 3% → 15.1%

share price at the notices 12.6–16.2p · now 5.3p 13 Oct 2025 4 Nov 2025 19 Nov 2025 26 Nov 2025 8 Dec 2025 29 Dec 2025

Seneca Partners Limited 15 Jan · 1 notice

4.1% → 9.9%

share price at the notices 19.4p · now 5.3p 15 Jan 2026

Directors

No open-market share purchases by directors in 12 months.

other SkinBioTherapeutics PLC announced that Simon Hewitson, an Executive Director and Chief Operating Officer, will be leaving the company due to personal reasons. The recruitment process for his replacement has already begun 14 Oct 2025

other SkinBioTherapeutics plc has announced directorate changes effective January 1, 2026, appointing Alyson Levett as a non-executive director and Chair of the Audit Committee, and promoting Emily Bertram to Chief Financial O 5 Jan 2026

other SkinBioTherapeutics plc announced that its Chief Financial Officer, Emily Bertram, will depart on June 30, 2026, after making significant contributions to the company's financial stewardship and governance, including ide 25 Jun 2026

Company filings. Not investment advice.